Book Value per Share: Intellia Therapeutics (NTLA)

Graphic logo of Intellia Therapeutics (NTLA)

The market valuation dynamics for Intellia Therapeutics (NTLA), which stands at 5.20, reflect the price action of the gene therapy developer. Intellia Therapeutics (NTLA) integrates ESG principles into bioethics and optimizes waste utilization. US centers are developing treatments for hereditary pathologies, leveraging key CRISPR patents. The business operates in an autonomous cycle, remaining a defensive asset independent of global economic downturns.

Intellia (NTLA) Equity per Share: for the period 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for intelliatx.com (NTLA)

- price and consensus price forecast:
Price Chart Intellia|NTLA - Price Target Chart
- market capitalization data:
Market Capitalization Intellia Therapeutics, Inc.|NTLA - Enterprise Value
- book capitalization data:
Book Value per Share Intellia Therapeutics|NTLA - Accounting Capitalization|Market Value to Book Value Ratio intelliatx.com|NTLA - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Intellia Therapeutics|NTLA - Long-Term Debt to Capital|Short-Term Debt to Capital Intellia Therapeutics, Inc.|NTLA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Intellia Therapeutics, Inc.|NTLA - Company Long-Term Indebtedness|Company Current Liabilities Intellia Therapeutics
Fundamental company valuation:Intellia Therapeutics
Manufactured products of intelliatx.com

Intellia Therapeutics (NTLA) is investing colossal resources into the development of CRISPR therapies to cure hereditary pathologies. The book value per share is calculated as the difference between total assets and liabilities, divided by the number of shares. This indicator determines the actual value of net assets, creating a financial safety cushion. A high level of this metric minimizes bankruptcy risks during prolonged R&D cycles. The historical trend of the book value per share clearly demonstrates the resilience of the issuer's capital.

Competitor analysis

TEM - Net Assets per Single Share|QGEN - Net Assets per Single Share|IONS: Book Value per Share|repligen.com (RGEN) - Book Value per Share|Book Value per Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRSP|Net Assets per Single Share Sema4 WGS|Equity per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM (Beam Therapeutics Inc.)|Book Value per Share sarepta.com SRPT|Book Value per Share TWST (Twist Bioscience, Inc.)|TXG: Net Assets per Share|Net Assets per Single Share Stoke|Equity per Share BioLife|Wave Life Sciences (WVE) - Accounting Value per Share|Book Price of a Share mazetx.com|Sionna Therapeutics - Book Value per Share|Net Asset Value per Share PRME (Prime Medicine Inc)|Net Assets per Single Share Taysha TSHA|uniQure Pharma - Net Assets per Single Share|MGTX - Net Assets per Single Share|RGNX - Net Assets per Single Share|Solid Biosciences - Book Value per Share|Ocugen Inc (OCGN) - Net Assets per Share|PACB (Pacific Biosciences of California) - Book Value per Share|Book Value per Share Benitec Corp (BNTC)|Design Therapeutics (DSGN) - Accounting Value per Share|Accounting Value of a Share rocketpharma.com RCKT|Accounting Value per Share 4D Molecular Therapeutics, Inc. (FDMT)|Book Price of a Share Lexeo Therapeutics Inc. LXEO|Book Value per Share Korro Bio, Inc (KRRO)|EDIT - Accounting Value of a Share|Book Value per Share SLN|PRQR (ProQR Therapeutics) - Net Asset Value per Share|CDXS - Net Assets per Single Share|Accounting Value of a Share Sangamo Therapeutics Inc.|Book Value per Share NAUT|Book Value per Share MGX (Metagenomi Therapeutics)|Precision BioSciences, Inc. (DTIL) - Net Assets per Single Share|Share Book Value Generation Bio Co GBIO|BOLD (Boundless Bio) - Book Value per Share|Exicure, Inc. (XCUR) - Net Asset Value per Share|IMNN: Accounting Value per Share|Book Value per Share Phio Pharmaceuticals Corp.|Mustang Bio Inc (MBIO) - Accounting Value per Share|Book Price of a Share TransCode|BNGO (Bionano Genomics, Inc.) - Book Value per Share|Net Assets per Share Applied DNA Sciences Inc (APDN)|Bluebird Bio - Book Value per Share|ImmunoPrecise Antibodies Ltd - Accounting Value per Share|Net Assets per Single Share OMGA (Omega Therapeutics)|OMIC: Net Assets per Share|Net Assets per Single Share Regulus Therapeutics Inc.|Equity per Share Syros Pharmaceuticals Inc.|Codex DNA (TBIO) - Accounting Value per Share|Book Price of a Share TCON|Net Assets per Single Share Unity Biotechnology (UBX)